Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review.
Abiraterone
Androgen receptor signaling inhibitors
Apalutamide
Enzalutamide
High-risk prostate cancer
Locally advanced prostate cancer
Neoadjuvant therapy
Radical prostatectomy
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
23
12
2020
accepted:
25
01
2021
pubmed:
14
2
2021
medline:
11
2
2022
entrez:
13
2
2021
Statut:
ppublish
Résumé
There is an urgent need to develop novel treatment strategies in patients with unfavorable intermediate- and high-risk localized prostate cancer (PCa) to optimize the outcome of these patients. Androgen receptor signaling inhibitors (ARSI) have demonstrated a survival benefit in metastatic hormonesensitive and castration-resistant PCa. A similar benefit might be expected in the localized setting. To perform a systematic review about the role of neoadjuvant ARSI in unfavorable intermediate and high-risk localized PCa. We performed a systematic review of the following databases: MEDLINE (PubMed), EMBASE, Cochrane Library and Web of Science. Publications of ASCO were consulted to identify meeting abstract with early results of ongoing trials. This systematic review was performed and reported in accordance with the PRISMA guidelines. Pathological complete response (pCR) following neoadjuvant ARSI treatment was observed in 4%-13% of the patients. Minimal residual disease response ranged from 36% to 73.9% when defined as residual cancer burden < 0.25 cm Despite intense neoadjuvant ARSI therapy, pCR is rarely attained and high proportions of pT3 disease are still observed at final pathology. In contrast, promising results are obtained in terms of PSMs. Long-term survival outcomes are eagerly awaited.
Identifiants
pubmed: 33580296
doi: 10.1007/s00345-021-03611-x
pii: 10.1007/s00345-021-03611-x
doi:
Substances chimiques
Androgen Receptor Antagonists
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3177-3185Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
doi: 10.3322/caac.21492
Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123
doi: 10.1200/JCO.2009.26.0133
D’Amico AV et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974
doi: 10.1001/jama.280.11.969
Van den Broeck T et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur. Urol. 0, (2018).
Shelley MD et al (2009) A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 35:9–17
doi: 10.1016/j.ctrv.2008.08.002
Tucci M et al (2019) Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Cancer Treat Rev 74:35–42
doi: 10.1016/j.ctrv.2019.01.002
Kinsey EN, Zhang T, Armstrong AJ (2020) Metastatic hormone-sensitive prostate cancer: a review of the current treatment landscape. Cancer J (United States) 26:64–75
Efstathiou E et al (2019) Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone. Eur Urol 76:418–424
doi: 10.1016/j.eururo.2019.05.010
McKay RR et al (2019) Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J. Clin. Oncol. JCO.18.01777. https://doi.org/10.1200/JCO.18.01777 .
Montgomery B et al (2017) Neoadjuvant enzalutamide prior to prostatectomy. Clin Cancer Res 23:2169–2176
doi: 10.1158/1078-0432.CCR-16-1357
Taplin M-E et al (2014) Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 32:3705–3715
doi: 10.1200/JCO.2013.53.4578
Efstathiou E et al (2020) Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC). J Clin Oncol 38:5504–5504
doi: 10.1200/JCO.2020.38.15_suppl.5504
McKay RR et al (2020) Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC). J Clin Oncol 38:5503–5503
doi: 10.1200/JCO.2020.38.15_suppl.5503
Cortazar P et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:164–172
doi: 10.1016/S0140-6736(13)62422-8
Mckay RR et al (2018) Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis 21:364–372
doi: 10.1038/s41391-017-0009-6
Page ST et al (2006) Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91:3850–3856
doi: 10.1210/jc.2006-0968
Mostaghel EA et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033–5041
doi: 10.1158/0008-5472.CAN-06-3332
Beltran H et al (2017) Impact of therapy on genomics and transcriptomics in high-risk prostate cance treated with neoadjuvant docetaxel and androgen deprivation therapy. Clin Cancer Res 23:6802–6811
doi: 10.1158/1078-0432.CCR-17-1034
Corcoran N et al (2015) The predictive value of ARv7 expression in localized prostate caner treated with abiraterone, degarelix, and bicalutamide. J Clin Oncol 33:71–71
doi: 10.1200/jco.2015.33.7_suppl.71
Sowalsky AG et al (2018) Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations. Cancer Res 78:4716–4730
doi: 10.1158/0008-5472.CAN-18-0610
Arora VK et al (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155:1309–1322
doi: 10.1016/j.cell.2013.11.012
Wyatt AW et al (2016) Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol 2:1598–1606
doi: 10.1001/jamaoncol.2016.0494
De Laere B et al (2019) TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin Cancer Res 25:1766–1773
doi: 10.1158/1078-0432.CCR-18-1943
Mateo J et al. Genomics of lethal prostate cancer at diagnosis and castration-resistance. J Clin Invest 130, (2019).
Castro E et al (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31:1748–1757
doi: 10.1200/JCO.2012.43.1882
Marshall CH et al (2019) Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis 22:59–65
doi: 10.1038/s41391-018-0086-1
Isaacsson Velho P et al (2019) Molecular characterization and clinical outcomes of primary gleason pattern 5 prostate cancer after radical prostatectomy. JCO Precis Oncol 3:1–13
Eastham JA et al (2020) Cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer. J Clin Oncol 38:3042–3050
doi: 10.1200/JCO.20.00315
Serritella A et al (2020) Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 38:91–91
doi: 10.1200/JCO.2020.38.6_suppl.91
De Bono JS et al (2019) Randomized phase II study evaluating AKT blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin Cancer Res 25:928–936
doi: 10.1158/1078-0432.CCR-18-0981
Ku SY, Gleave ME, Beltran H (2019) Towards precision oncology in advanced prostate cancer. Nat Rev Urol 16:645–654
doi: 10.1038/s41585-019-0237-8
de Bono J et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091–2102
doi: 10.1056/NEJMoa1911440